Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate Single and Multiple (Seven) Oral Doses of SRT2104 on the Endotoxin Induced Inflammatory Response in Healthy Male Subjects

NCT01014117 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01014117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01014117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate Single and Multiple (Seven) Oral Doses of SRT2104 on the Endotoxin Induced Inflammatory Response in Healthy Male Subjects
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
December 9, 2009
Completion date
May 10, 2010
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis